• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

卡非佐米对两名复发多发性骨髓瘤日本患者的心脏毒性

Cardiotoxicity of Carfilzomib in Two Japanese Patients with Relapsed Multiple Myeloma.

作者信息

Ikoma Takenori, Saotome Masao, Sano Makoto, Suwa Kenichiro, Naruse Yoshihisa, Ohtani Hayato, Urushida Tsuyoshi, Nagata Yasuyuki, Ono Takaaki, Maekawa Yuichiro

机构信息

Department of Cardiology, Internal Medicine 3, Hamamatsu University School of Medicine, Japan.

Department of Hematology, Internal Medicine 3, Hamamatsu University School of Medicine, Japan.

出版信息

Intern Med. 2019 Jun 1;58(11):1577-1581. doi: 10.2169/internalmedicine.2194-18. Epub 2019 Feb 1.

DOI:10.2169/internalmedicine.2194-18
PMID:30713316
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6599935/
Abstract

Although multiple myeloma (MM) had been an incurable hematological malignancy with a poor prognosis, recent advances in novel anti-neoplastic agents, including carfilzomib (a proteasome inhibitor), have improved the prognosis. We herein report two cases of congestive heart failure in patients treated with carfilzomib. Although there are some reports on the cardiotoxicity of carfilzomib, to our knowledge, this is the first report on the cardiac involvement of carfilzomib in Japanese MM patients. We review the critical points from our two cases, with the aim of avoiding carfilzomib-associated heart failure in MM patients.

摘要

尽管多发性骨髓瘤（MM）曾是一种预后不良的无法治愈的血液系统恶性肿瘤，但包括卡非佐米（一种蛋白酶体抑制剂）在内的新型抗肿瘤药物的最新进展改善了预后。我们在此报告两例接受卡非佐米治疗的患者发生充血性心力衰竭的病例。尽管有一些关于卡非佐米心脏毒性的报道，但据我们所知，这是关于卡非佐米在日本MM患者中引起心脏受累的首例报告。我们从这两例病例中总结关键点，旨在避免MM患者发生与卡非佐米相关的心力衰竭。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d984/6599935/62fadec15985/1349-7235-58-1577-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d984/6599935/5b18a655d12f/1349-7235-58-1577-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d984/6599935/a54f85e9669d/1349-7235-58-1577-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d984/6599935/c6e2400c5552/1349-7235-58-1577-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d984/6599935/62fadec15985/1349-7235-58-1577-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d984/6599935/5b18a655d12f/1349-7235-58-1577-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d984/6599935/a54f85e9669d/1349-7235-58-1577-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d984/6599935/c6e2400c5552/1349-7235-58-1577-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d984/6599935/62fadec15985/1349-7235-58-1577-g004.jpg

相似文献

1
Cardiotoxicity of Carfilzomib in Two Japanese Patients with Relapsed Multiple Myeloma.卡非佐米对两名复发多发性骨髓瘤日本患者的心脏毒性
Intern Med. 2019 Jun 1;58(11):1577-1581. doi: 10.2169/internalmedicine.2194-18. Epub 2019 Feb 1.
2
Incidence and risk of cardiac toxicities in patients with relapsed and refractory multiple myeloma treated with carfilzomib.接受卡非佐米治疗的复发难治性多发性骨髓瘤患者心脏毒性的发生率和风险
Drug Des Devel Ther. 2018 May 30;12:1525-1531. doi: 10.2147/DDDT.S159818. eCollection 2018.
3
Carfilzomib: A new proteasome inhibitor for relapsed or refractory multiple myeloma.卡非佐米：一种用于复发或难治性多发性骨髓瘤的新型蛋白酶体抑制剂。
J Oncol Pharm Pract. 2013 Dec;19(4):348-54. doi: 10.1177/1078155212470388. Epub 2013 Jan 4.
4
Heart failure secondary to carfilzomib-induced heart block in multiple myeloma patients.多发性骨髓瘤患者中因卡非佐米诱导的心脏传导阻滞继发的心衰
J Oncol Pharm Pract. 2017 Mar;23(2):152-156. doi: 10.1177/1078155215626788. Epub 2016 Jul 7.
5
Management of Carfilzomib-Associated Cardiac Adverse Events.卡非佐米相关心脏不良事件的管理
Clin Lymphoma Myeloma Leuk. 2016 May;16(5):241-5. doi: 10.1016/j.clml.2016.01.008. Epub 2016 Feb 4.
6
Carfilzomib: A Tale of a Heartbreaking Moment: Case Report and Concise Review of the Literature.卡非佐米：一个心碎时刻的故事：病例报告及文献简要综述
Cardiovasc Hematol Disord Drug Targets. 2019;19(3):253-258. doi: 10.2174/1871529X19666181205100705.
7
Renal failure among multiple myeloma patients utilizing carfilzomib and associated factors in the "real world".多发性骨髓瘤患者在“真实世界”中使用卡非佐米治疗后的肾衰竭及其相关因素。
Ann Hematol. 2021 May;100(5):1261-1266. doi: 10.1007/s00277-021-04420-3. Epub 2021 Jan 21.
8
Cardiotoxicity associated with carfilzomib: systematic review and meta-analysis.与卡非佐米相关的心脏毒性：系统评价与荟萃分析。
Leuk Lymphoma. 2018 Nov;59(11):2557-2569. doi: 10.1080/10428194.2018.1437269. Epub 2018 Feb 21.
9
Evaluation of Cardiovascular Toxicity Associated with Treatments Containing Proteasome Inhibitors in Multiple Myeloma Therapy.多发性骨髓瘤治疗中含蛋白酶体抑制剂治疗相关心血管毒性的评估
High Blood Press Cardiovasc Prev. 2018 Jun;25(2):209-218. doi: 10.1007/s40292-018-0256-1. Epub 2018 Mar 26.
10
Carfilzomib: a second-generation proteasome inhibitor for the treatment of relapsed and refractory multiple myeloma.卡非佐米：第二代蛋白酶体抑制剂，用于治疗复发和难治性多发性骨髓瘤。
Ann Pharmacother. 2013 Jan;47(1):56-62. doi: 10.1345/aph.1R561. Epub 2013 Jan 8.

引用本文的文献

1
BIBR1532 inhibits proliferation and enhances apoptosis in multiple myeloma cells by reducing telomerase activity.BIBR1532 通过降低端粒酶活性抑制多发性骨髓瘤细胞的增殖并增强其凋亡。
PeerJ. 2023 Nov 8;11:e16404. doi: 10.7717/peerj.16404. eCollection 2023.

本文引用的文献

1
Arterial Hypertension and Multiple Myeloma: Physiopathology and Cardiovascular Risk and 'Practical' Indications in Patients Receiving Carfilzomib.动脉高血压与多发性骨髓瘤：接受卡非佐米治疗患者的病理生理学、心血管风险及“实用”指征
Curr Hypertens Rev. 2019;15(1):47-53. doi: 10.2174/1573402114666180611110547.
2
Cardiotoxicity associated with carfilzomib: systematic review and meta-analysis.与卡非佐米相关的心脏毒性：系统评价与荟萃分析。
Leuk Lymphoma. 2018 Nov;59(11):2557-2569. doi: 10.1080/10428194.2018.1437269. Epub 2018 Feb 21.
3
Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline.
成人癌症幸存者心功能障碍的预防和监测：美国临床肿瘤学会临床实践指南。
J Clin Oncol. 2017 Mar 10;35(8):893-911. doi: 10.1200/JCO.2016.70.5400. Epub 2016 Dec 5.
4
Carfilzomib and the cardiorenal system in myeloma: an endothelial effect?卡非佐米与骨髓瘤中的心脏肾脏系统：内皮效应？
Blood Cancer J. 2016 Jan 15;6(1):e384. doi: 10.1038/bcj.2015.112.
5
Carfilzomib for the treatment of patients with relapsed and/or refractory multiple myeloma.卡非佐米用于治疗复发和/或难治性多发性骨髓瘤患者。
Future Oncol. 2015;11(15):2121-36. doi: 10.2217/fon.15.123. Epub 2015 Jun 30.
6
Cardiac complications in relapsed and refractory multiple myeloma patients treated with carfilzomib.接受卡非佐米治疗的复发难治性多发性骨髓瘤患者的心脏并发症
Blood Cancer J. 2015 Jan 16;5(1):e272. doi: 10.1038/bcj.2014.93.
7
Case series discussion of cardiac and vascular events following carfilzomib treatment: possible mechanism, screening, and monitoring.卡非佐米治疗后心脏和血管事件的病例系列讨论：可能机制、筛查与监测
BMC Cancer. 2014 Dec 4;14:915. doi: 10.1186/1471-2407-14-915.
8
Patterns of cardiac toxicity associated with irreversible proteasome inhibition in the treatment of multiple myeloma.在多发性骨髓瘤治疗中与不可逆蛋白酶体抑制相关的心脏毒性模式。
J Card Fail. 2015 Feb;21(2):138-44. doi: 10.1016/j.cardfail.2014.11.008. Epub 2014 Nov 26.
9
Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients.多发性骨髓瘤患者的生存率持续提高：老年患者早期死亡率和结局的变化。
Leukemia. 2014 May;28(5):1122-8. doi: 10.1038/leu.2013.313. Epub 2013 Oct 25.
10
Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies.单药卡非佐米的综合安全性概况：来自 4 项 II 期临床研究中纳入的 526 例患者的经验。
Haematologica. 2013 Nov;98(11):1753-61. doi: 10.3324/haematol.2013.089334. Epub 2013 Aug 9.